Clinical Trial Update: A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and pharmacokinetics of PCS6422 (eniluracil) in combination with capecitabine in patients with advanced, refractory GI tract…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastrointestinal Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• PCS6422 (eniluracil)

Snippet

Sponsor: Processa Pharmaceuticals | Conditions: Advanced Cancer, Refractory Cancer | Phase 1 | Status: COMPLETED